Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and tumour molecular subtypes in prostate cancer management

17 Mar 2025

Abstract excerpt

Background Prostate cancer is defined by the suppression of genes that suppress tumours and the activation of proto-oncogenes. These are the hallmarks of prostate cancer, and they have been linked to numerous genomic variations, which lead to unfavourable treatment outcomes. Prostate cancer can be categorised into various risk groups of tumour molecular subtypes grounded in the idea of genomic structural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40165885
DOI: 10.3389/fonc.2025.1521204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and tumour molecular subtypes in prostate cancer managementPMID 40165885Read ↗

Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.Semantic proximity Read ↗

Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.Semantic proximity Read ↗

Molecular Diagnosis of Prostate Cancer: <i>PCA3</i> and <i>TMPRSS2:ERG</i> Gene FusionSemantic proximity Read ↗

Advancing Precision Medicine for Prostate Cancer Through GenomicsSemantic proximity Read ↗

Molecular landscape of prostate cancer: Implications for current clinical trialsSemantic proximity Read ↗

Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumorsSemantic proximity Read ↗

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancerSemantic proximity Read ↗

The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.Semantic proximity Read ↗

Prostate cancer genotyping for risk stratification and precision treatmentSemantic proximity Read ↗

DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Semantic proximity Read ↗

The mutational landscape of prostate cancer.Semantic proximity Read ↗

TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.